Treatment of catecholaminergic polymorphic ventricular tachycardia in mice using novel RyR2-modifying drugs.

@article{Li2017TreatmentOC,
  title={Treatment of catecholaminergic polymorphic ventricular tachycardia in mice using novel RyR2-modifying drugs.},
  author={Na Li and Qiongling Wang and Martha Sibrian-Vazquez and Robert Carl Klipp and Julia O. Reynolds and Tarah A Word and Larry D. Scott and Guy Salama and Robert M. Strongin and Jonathan J. Abramson and Xander H T Wehrens},
  journal={International journal of cardiology},
  year={2017},
  volume={227},
  pages={
          668-673
        }
}
RATIONALE Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a potentially lethal arrhythmic disorder caused by mutations in the type-2 ryanodine receptor (RyR2). Mutant RyR2 cause abnormal Ca2+ leak from the sarcoplasmic reticulum (SR), which is associated with the development of arrhythmias. OBJECTIVE To determine whether derivatives of tetracaine, a local anesthetic drug with known RyR2 inhibiting action, could prevent CPVT induction by suppression of RyR2-mediated SR Ca2… CONTINUE READING
3 Citations
30 References
Similar Papers

Citations

Publications citing this paper.

References

Publications referenced by this paper.
Showing 1-10 of 30 references

Similar Papers

Loading similar papers…